Publication Name	World Journal of Clinical Cases
Manuscript ID	83329
Country	Italy

Received	2023-01-20 15:45
Peer-Review Started	2023-01-20 15:48
To Make the First Decision
Return for Revision	2023-02-23 16:05
Revised	2023-03-10 07:16
Second Decision	2023-03-28 03:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-03-29 07:58
Articles in Press	2023-03-29 07:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-04-07 07:14
Publish the Manuscript Online	2023-04-25 23:32

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
Manuscript Source	Invited Manuscript
All Author List	Federica Crispino, Andrea Michielan, Mauro Grova, Chiara Tieppo, Marta Mazza, Teresa Marzia Rogger and Franco Armelao
ORCID	Author(s) ORCID Number Federica Crispino http://orcid.org/0000-0001-7643-3775 Andrea Michielan http://orcid.org/0000-0003-1353-0935 Mauro Grova http://orcid.org/0000-0001-8978-8604 Chiara Tieppo http://orcid.org/0000-0001-5805-7892 Marta Mazza http://orcid.org/0000-0002-8231-8789 Teresa Marzia Rogger http://orcid.org/0000-0002-0395-4219 Franco Armelao http://orcid.org/0000-0003-4307-9479
Funding Agency and Grant Number
Corresponding Author	Andrea Michielan, MD, Doctor, Doctor, Gastroenterology and Digestive Endoscopy Unit, Department of Surgery, Santa Chiara Hospital, Azienda Provinciale per i Sevizi Sanitari, Largo Medaglie d’oro 9, Trento 38122, Italy. andrea.michielan@apss.tn.it
Key Words	Exit strategy; Biologic withdrawal; Drug holiday; Vedolizumab; Ustekinumab; Tofacitinib
Core Tip	Clinicians are still uncertain about whether and when to consider stopping conventional therapies in inflammatory bowel disease (IBD) for fear of disease relapse. Our review aims to shed light on the optimal discontinuation strategies for biologics and the small molecule tofacitinib in IBD.
Publish Date	2023-04-25 23:32
Citation	Crispino F, Michielan A, Grova M, Tieppo C, Mazza M, Rogger TM, Armelao F. Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors. World J Clin Cases 2023; 11(12): 2657-2669
URL	https://www.wjgnet.com/2307-8960/full/v11/i12/2657.htm
DOI	https://dx.doi.org/10.12998/wjcc.v11.i12.2657

Full Article (PDF)	WJCC-11-2657.pdf
Full Article (Word)	WJCC-11-2657.docx
Manuscript File	83329_Auto_Edited-JLW.docx
Answering Reviewers	83329-Answering reviewers.pdf
Audio Core Tip	83329-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	83329-Conflict-of-interest statement.pdf
Copyright License Agreement	83329-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	83329-Language certificate.pdf
Peer-review Report	83329-Peer-review(s).pdf
Scientific Misconduct Check	83329-Bing-Ma YJ-2.jpg
Scientific Editor Work List	83329-Scientific editor work list.pdf
CrossCheck Report	83329-CrossCheck Report.pdf